600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1
- Resource Type
- article
- Source
- Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2051-1426